As both T2DM and TNBC are inflammatory diseases, an in vitro study reported the important role of the pro-inflammatory IL-6 signaling in TNBC survival and aggressiveness, suggesting IL-6 inhibition as a potential therapeutic intervention and/or new adjuvant therapy to improve the clinical outcome of TNBC patients [50]. This evidence concerns the gene IL6 and type 2 diabetes mellitus.